Kirsten M. Selns1, 2, Ingrid Susann Gribbestad1, 2, Helena Bertilsson3, 4, Alan Wright5, Anders Angelsen4, Arend Heerschap, 15, May-Britt Tessem1, 2
1Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway; 2St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway; 3Department of Laboratory Medicine and Children's and Women's Helath, Norwegian University of Science and Technology, Trondheim, Norway; 4Department of Urology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway; 5Department of Radiology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
MR metabolic profiling of the prostate is promising as an additional diagnostic approach to separate indolent from aggressive prostate cancer. MR metabolite ratios (choline+creatine+spermine/citreate) obtained non-invasively from patients in vivo by magnetic resonance spectroscopic imaging (MRSI) and from tissue samples ex vivo by high resolution magic angle spinning (HR-MAS) MR spectroscopy (MRS) correlate to Gleason score (&[rho]=0.77 and &[rho]=0.69, respectively, p<0.001). There is also a strong positive correlation between metabolite ratios from in vivo and ex vivo MR spectra of matched regions.